|
Updated: November 17, 2016
P1101 is a novel engineered PEGylated interferon alpha 2b currently being investigated by PharmaEssentia. P1101 boasts a higher purity composition compared to currently marketed PEGylated interferon alphas such as PEG-Intron by Merck and Pegasys by Roche, which may improve the side effect profile. Clinical trials are currently underway to evaluate P1101 in a number of treatments for hematological disorders and infectious disease.
|
Archives
May 2020
Topics
All
|